Foster City, CA, United States of America

Mark Stephen Smyth

USPTO Granted Patents = 39 (Patent Applications = 22)

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 4.0

ph-index = 21

Forward Citations = 841(Granted Patents)

Location History:

San Mateo, CA (US) (2009 - 2012)
Foster City, CA (US) (2001 - 2019)
Granite Bay, CA (US) (2020 - 2021)

Company Filing History:

17 out of 50

Onyx Therapeutics, Inc.

Onyx Technologies, Inc.

patent

5. 1 out of 70

Portola Pharmaceuticals, Inc.

patents

6. 1 out of 4,442

Eli Lilly and Company

patents

7. 2 out of 832,680

Other

patents

Years Active: 2001-2021

Loading Chart...

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10961251 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2021-03-30),

2. 10752634 - Crystalline forms of a brutons tyrosine kinase inhibitor (2020-08-25),

3. 10294232 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),

4. 10294231 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-05-21),

5. 10266540 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2019-04-23),

6. 10125140 - Crystalline forms of a bruton's tyrosine kinase inhibitor (2018-11-13),

7. 10106548 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2018-10-23),

8. 10065968 - Crystalline forms of a bruton's tyrosine kinase inhibitor (2018-09-04),

9. 9828383 - Crystalline forms of a bruton's tyrosine kinase inhibitor (2017-11-28),

10. 9725455 - Crystalline forms of a bruton's tyrosine kinase inhibitor (2017-08-08),

11. 9713617 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2017-07-25),

12. 9657058 - Compounds for enzyme inhibition (2017-05-23),

13. 9540382 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2017-01-10),

14. 9296753 - Crystalline forms of a Bruton's tyrosine kinase inhibitor (2016-03-29),

15. 9012463 - Inhibitors of bruton's tyrosine kinase (2015-04-21),

Sure, here is the article about inventor Mark Stephen Smyth:

Title: Mark Stephen Smyth - Pioneering Innovations in Pharmaceutical Treatments

Introduction:

Mark Stephen Smyth, based in Foster City, CA (US), is a renowned inventor with a remarkable contribution to the field of pharmaceuticals. With an impressive portfolio of 39 patents, his work has significantly impacted the treatment of various diseases and conditions.

Latest Patents:

Among his latest patents is the groundbreaking invention of crystalline forms of a Bruton's tyrosine kinase inhibitor. This inhibitor, recognized as 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, has opened new avenues in the treatment of autoimmune diseases, cancer (including lymphoma), and inflammatory conditions. The pharmaceutical compositions developed by Smyth have shown promising results in combating these ailments.

Career Highlights:

Mark Stephen Smyth has made significant contributions while working at esteemed pharmaceutical companies like Onyx Therapeutics, Inc. and Pharmacyclics, Inc. His expertise and innovative approach have been instrumental in developing advanced pharmaceutical products for improving patient outcomes.

Collaborations:

Throughout his career, Smyth has collaborated with talented individuals in the industry, including his coworkers Guy J Laidig and Erick A Goldman. Together, they have synergized their efforts to drive forward groundbreaking research in pharmaceuticals.

Conclusion:

In conclusion, Mark Stephen Smyth stands out as a visionary inventor whose inventive spirit and dedication have reshaped the landscape of pharmaceutical treatments. His patents and collaborations serve as a testament to his commitment to advancing healthcare and improving the quality of life for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.